<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02225574</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0128</org_study_id>
    <secondary_id>NCI-2015-00044</secondary_id>
    <nct_id>NCT02225574</nct_id>
  </id_info>
  <brief_title>An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)</brief_title>
  <official_title>An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Array BioPharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to find the highest tolerated dose of the&#xD;
      combination of nilotinib and MEK-162 that can be given to patients with CML or acute&#xD;
      leukemia. Researchers also want to learn if the drug combination can help to control the&#xD;
      disease. The safety of the drug combination will also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be assigned to a study&#xD;
      group based on when you join this study. Up to 5 groups of up to 6 participants will be&#xD;
      enrolled in Phase 1 of the study, and up to 60 participants will be enrolled in Phase 2.&#xD;
&#xD;
      If you are enrolled in Phase 1, the dose of nilotinib and MEK-162 you receive will depend on&#xD;
      when you joined this study. The first group of participants will receive the starting dose&#xD;
      combination level. The next group will receive a higher dose of MEK-162 than Group 1, if no&#xD;
      intolerable side effects were seen. If intolerable side effects are seen, the next group may&#xD;
      receive a lower dose level of nilotinib and/or MEK-162. This will continue until the highest&#xD;
      tolerable combination dose is found.&#xD;
&#xD;
      If you are enrolled in Phase 2, you will receive nilotinib and MEK-162 at the highest dose&#xD;
      that was tolerated in Phase 1.&#xD;
&#xD;
      Study Treatment:&#xD;
&#xD;
      You will take nilotinib and MEK-162 two times every day by mouth.&#xD;
&#xD;
      Participants enrolled in Phase 1 of the study will start taking MEK-162 on Day 1 and&#xD;
      nilotinib on Day 2.&#xD;
&#xD;
      Participants in Phase 2 of the study will be divided in 2 groups: one group will start&#xD;
      MEK-162 on Day 1 and nilotinib on Day 2, while the other group will start MEK-162 on Day 1&#xD;
      and nilotinib on Day 8. You will be placed in a Phase 2 treatment group based on the&#xD;
      characteristics of your disease type.&#xD;
&#xD;
      You will be given a drug diary and asked to write down what time you take the study drugs&#xD;
      every day. Bring in any unused study drugs and bottles to each study visit.&#xD;
&#xD;
      Each cycle is 28 days.&#xD;
&#xD;
      If the disease does not appear to get better after 1 or 3 cycles, you may be able to receive&#xD;
      a higher dose of the study drug as long as you are not already receiving the highest dose&#xD;
      planned for this study. The study doctor will tell you if you can receive a higher dose.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      On Days 1 and 8 of Cycle 1:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Blood (about 2-3 tablespoons) and urine will be collected for routine tests.&#xD;
&#xD;
        -  You will have an EKG.&#xD;
&#xD;
      At the end of Cycle 1:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Blood (about 2-3 tablespoons) and urine will be collected for routine tests.&#xD;
&#xD;
        -  You will have an EKG and either a MUGA scan or an ECHO.&#xD;
&#xD;
        -  You will complete a questionnaire about how you are feeling.&#xD;
&#xD;
        -  If the doctor thinks it is needed, you will have a bone marrow aspirate to check the&#xD;
           status of the disease.&#xD;
&#xD;
      At the end of Cycles 2, 3, and every 3 cycles after that (6, 9, 12, and so on):&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Blood (about 2-3 tablespoons) and urine will be collected for routine tests.&#xD;
&#xD;
        -  You will have an EKG.&#xD;
&#xD;
        -  You will complete a questionnaire about how you are feeling.&#xD;
&#xD;
      At the end of Cycles 2, 3, 6, 9, and 12, blood (about 3-4 tablespoons each time) will be&#xD;
      drawn for tests to check how the disease is responding to therapy. If the doctor thinks it is&#xD;
      needed, these tests may be performed more often.&#xD;
&#xD;
      Every 8-12 weeks, you will have a MUGA scan or an ECHO.&#xD;
&#xD;
      You will have an eye exam by an eye doctor at the end of Cycles 2, 3, 6, 9, and 12, and then&#xD;
      every 3 months after that until the End of Study Visit.&#xD;
&#xD;
      You will have blood draws and/or bone marrow aspirations at any time that the doctor thinks&#xD;
      it is needed while you are on study.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You can take up to 12 cycles of nilotinib and MEK-162 on study. If the disease responds a&#xD;
      certain way (called a hematological response) while you are on study, you may be able to&#xD;
      continue taking the study drugs longer than 12 months, as long as the doctor thinks you are&#xD;
      benefiting from the treatment. Even if the disease has not responded in this way, you may be&#xD;
      able to continue taking the study drugs if the doctor thinks it is in your best interest. You&#xD;
      will no longer be able to take the study drug if the disease gets worse, if intolerable side&#xD;
      effects occur, or if you are unable to follow study directions.&#xD;
&#xD;
      Your participation on the study will be over after the follow-up visits.&#xD;
&#xD;
      End-of-Study Visit:&#xD;
&#xD;
      If you come off study before the end of Cycle 12, the following tests and procedures will be&#xD;
      performed:&#xD;
&#xD;
        -  You will have a physical exam.&#xD;
&#xD;
        -  Blood (about 2-3 tablespoons) and urine will be collected for routine tests.&#xD;
&#xD;
        -  You will have an EKG and either an ECHO or a MUGA scan.&#xD;
&#xD;
        -  You will have an eye exam by an eye doctor.&#xD;
&#xD;
        -  You will complete a questionnaire about how you are feeling.&#xD;
&#xD;
        -  If the doctor thinks it is needed, you will have a bone marrow aspirate to check the&#xD;
           status of the disease.&#xD;
&#xD;
      If you come off study at the end of Cycle 12, you will not have the End of Study visit.&#xD;
&#xD;
      Follow-Up:&#xD;
&#xD;
      You will be called about 30 days after you go off study and asked if you have had any side&#xD;
      effects and/or any new treatment(s). This call will last about 5 minutes.&#xD;
&#xD;
      This is an investigational study. Nilotinib is FDA approved and commercially available to&#xD;
      treat CML and philadelphia-positive acute leukemia. MEK-162 is not FDA approved or&#xD;
      commercially available. It is currently being used for research purposes only. The&#xD;
      combination of nilotinib and MEK-162 to treat CML and Philadelphia-positive acute leukemia is&#xD;
      investigational. The study doctor can explain how the study drugs are designed to work.&#xD;
&#xD;
      Up to 90 patients will take part in this study. All will be enrolled at MD Anderson Cancer&#xD;
      Center.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Accrual - Only 1 patient enrolled in Phase 1 - Study never went to Phase II&#xD;
  </why_stopped>
  <start_date type="Actual">March 11, 2015</start_date>
  <completion_date type="Actual">February 2, 2017</completion_date>
  <primary_completion_date type="Actual">February 2, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of MEK-162 and Nilotinib</measure>
    <time_frame>28 days</time_frame>
    <description>MTD defined as maximum daily oral dose at which &lt;33% of patients experience a dose limiting toxicity (DLT) during first 28 days. DLT defined by events that are clinically significant and at least possibly related to study drug occurring during the first 4 weeks of therapy. Toxicities reported on a scale of 1-4 according to the NCI criteria Common Terminology Criteria for Adverse Events (CTCAE).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate for Advanced CML and Philadelphia-Positive Acute Leukemia</measure>
    <time_frame>28 days</time_frame>
    <description>For CML response defined as major hematological response (MaHR) at the end of the 1st cycle. For Philadelphia-positive acute leukemia response defined as achievement of complete remission(CR)/CR with incomplete platelet recovery (CRp)/ CR with insufficient hematological recovery (CRi)/partial remission (PR)/morphologic leukemia free (MLF) at the end of the 1st cycle.&#xD;
For Philadelphia-positive acute leukemia response defined as improvement in one response category (eg, from complete hematological response [CHR] to any cytogenetic response, from minor cytogenetic response to partial cytogenetic response, from partial cytogenetic response to complete cytogenetic response, from complete cytogenetic response to major molecular response [MMR]) at end of the 3rd cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate for Chronic Phase CML</measure>
    <time_frame>After 3, 28 day cycles</time_frame>
    <description>Response defined as improvement in one response category (eg, from complete hematological response [CHR] to any cytogenetic response, from minor cytogenetic response to partial cytogenetic response, from partial cytogenetic response to complete cytogenetic response, from complete cytogenetic response to major molecular response [MMR]) at end of the 3rd cycle.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Advanced CML + Philadelphia positive Acute Leukemia-Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.&#xD;
Phase 1 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.&#xD;
Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.&#xD;
Phase 2 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on Day 1 of a 28 day cycle.&#xD;
Phase 2 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Phase CML - Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.&#xD;
Phase 1 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.&#xD;
Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.&#xD;
Phase 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle.&#xD;
Phase 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEK-162</intervention_name>
    <description>Phase 1: Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of MEK-162: 30 mg by mouth twice a day on starting on Day 1 of a 28 day cycle.&#xD;
Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on on Day 1 of a 28 day cycle.&#xD;
Phase 1 Chronic Phase CML - Group 2 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.&#xD;
Phase 2 Chronic Phase CML - Group 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle.</description>
    <arm_group_label>Advanced CML + Philadelphia positive Acute Leukemia-Group 1</arm_group_label>
    <arm_group_label>Chronic Phase CML - Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nilotinib</intervention_name>
    <description>Phase 1 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.&#xD;
Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle.&#xD;
Phase 1 Chronic Phase CML - Group 2 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.&#xD;
Phase 2 Chronic Phase CML - Group 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle.</description>
    <arm_group_label>Advanced CML + Philadelphia positive Acute Leukemia-Group 1</arm_group_label>
    <arm_group_label>Chronic Phase CML - Group 2</arm_group_label>
    <other_name>AMN107</other_name>
    <other_name>Tasigna</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.</description>
    <arm_group_label>Advanced CML + Philadelphia positive Acute Leukemia-Group 1</arm_group_label>
    <arm_group_label>Chronic Phase CML - Group 2</arm_group_label>
    <other_name>Surveys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients 18 years of age or older with advanced CML (CML-AP, CML-BP and Philadelphia&#xD;
             chromosome-positive acute leukemia) or refractory chronic phase CML are eligible, as&#xD;
             defined as follows: The phase I portion of the study will be conducted first in&#xD;
             advanced phase (accelerated phase CML, blast phase CML or Philadelphia-positive acute&#xD;
             leukemia) patients. Once MTD is identified, a cohort of 6 patients with CML chronic&#xD;
             phase who have failed prior therapy with at least two tyrosine kinase inhibitor will&#xD;
             be treated at the MTD to determine if this dose is also acceptable for chronic phase&#xD;
             patients. The phase II will be conducted in two treatment arms as follows: Treatment&#xD;
             Arm A (Advanced phase disease) and treatment Arm B (Therapy for CP-CML&#xD;
             refractory/resistant/suboptimally responding to at least two prior TKI's)&#xD;
&#xD;
          2. (Cont - Inclusion Criteria #1) CML-AP is defined by the presence of one of the&#xD;
             following: a. 15-29% blasts in peripheral blood (PB) or bone marrow (BM), b.&gt;20%&#xD;
             basophils in PB or BM, c.&gt;30% blasts plus promyelocytes (with blasts &lt;30%) in PB or&#xD;
             BM, d.&lt;100 x109/L platelets unrelated to therapy, or Clonal cytogenetics evolution&#xD;
             (i.e., the presence of cytogenetic abnormalities other than the Philadelphia&#xD;
             chromosome) except if only present at the time of diagnosis and not associated with&#xD;
             other features of accelerated phase. CML-BP is defined by the presence of &gt;/=30%&#xD;
             blasts in the bone marrow and/or peripheral blood or the presence of extramedullary&#xD;
             disease, with myeloid or lymphoid blast morphology. Philadelphia-chromosome acute&#xD;
             leukemias are eligible and defined by &gt;/=20% blasts in the peripheral blood or bone&#xD;
             marrow at the time of diagnosis.&#xD;
&#xD;
          3. Patients with advanced phase CML or acute leukemia must have failed at least one prior&#xD;
             TKI. Patients with chronic phase CML must have failed, have resistance or suboptimal&#xD;
             response to at least two tyrosine kinase inhibitors, or have intolerance to two prior&#xD;
             tyrosine kinase inhibitors. For patient with prior intolerance, they should have&#xD;
             received at least 2 TKI and experienced intolerance to one TKI and&#xD;
             resistance/suboptimal&#xD;
&#xD;
          4. (Cont - Inclusion Criteria #3) a. Failure to tyrosine kinase inhibitors will be&#xD;
             defined per European-Leukemia-Net (ELN) recommendations b.Resistance or suboptimal&#xD;
             response to at least two prior Abl-kinase inhibitor, specifically: i.Chronic-phase&#xD;
             with resistance to imatinib, dasatinib, nilotinib, bosutinib or ponatinib defined as&#xD;
             1. Loss of CCyR at any time or failure to achieve CCyR after &gt;/=18 months 2. Loss of&#xD;
             MCyR at any time or failure to achieve PCyR after &gt;/=12 months 3. Failure to achieve&#xD;
             any CyR (ie, &gt;/= 65% Ph+) after &gt;/= 6 months 4. Hematologic relapse or failure to&#xD;
             achieve CHR after &gt;/=3 months ii. Chronic-phase with suboptimal response to imatinib,&#xD;
             defined as 1. Failure to achieve PCyR after &gt;/= 6 months 2. Failure to achieve CCyR&#xD;
             after &gt;/=12 months iii. Chronic-phase with suboptimal response to nilotinib,&#xD;
             bosutinib, dasatinib or ponatinib, defined as 1. Failure to achieve PCyR after &gt;/= 3&#xD;
             months 2. Failure to achieve CCyR after &gt;/= 6 months of therapy&#xD;
&#xD;
          5. Patients with cytogenetic BCR-Abl variants and additional chromosomal abnormalities&#xD;
             ('clonal evolution') will be eligible. Cytogenetics to be performed, but results are&#xD;
             not required to start therapy in patients with hematologic progression&#xD;
&#xD;
          6. Patients who have failed nilotinib, including those who are refractory to nilotinib at&#xD;
             any dose or have relapsed on nilotinib at any dose will be eligible for the study.&#xD;
             Patients currently on nilotinib will continue on their prescribed dose of nilotinib&#xD;
             and MEK-162 will be added based on the current cohort level in phase I or at the&#xD;
             established MTD in phase II. In the instance the nilotinib dose is greater than the&#xD;
             current cohort (in phase 1) or the MTD (in phase 2) patients will be dose reduced to&#xD;
             the dosage as prescribed by protocol and then dose escalated as allowed in protocol at&#xD;
             the PIs discretion.&#xD;
&#xD;
          7. For the phase I portion of the study, patients who had received prior therapy with&#xD;
             nilotinib should have been able to tolerate the dose equivalent to the starting dose&#xD;
             of nilotinib in the dose level at which the patient is being entered. Patients who&#xD;
             previously received nilotinib but never at the dose being proposed are eligible&#xD;
             provided they tolerated the maximum dose they were prescribed with no grade 3 or 4&#xD;
             toxicity not responding to optimal management.&#xD;
&#xD;
          8. Patients must have been off all prior therapy for CML for 2 weeks prior to start of&#xD;
             study therapy and recovered from the toxic effects of that therapy. Exceptions to&#xD;
             these are hydroxyurea and TKIs (including but not limited to imatinib, nilotinib,&#xD;
             dasatinib, ponatinib and bosutinib), which should be discontinued â‰¥48 hrs prior to the&#xD;
             start of therapy. Patients who are receiving nilotinib prior to enrollment do not have&#xD;
             to discontinue this agent prior to start of study therapy&#xD;
&#xD;
          9. Eastern Cooperative Oncology Group (ECOG) performance status &lt;/=2&#xD;
&#xD;
         10. Men and women of childbearing potential should practice effective methods of&#xD;
             contraception. Men and women of childbearing potential are defined as: a male that has&#xD;
             not been surgically sterilized or female that has not been amenorrheic for at least 12&#xD;
             consecutive months or that has not been surgically sterilized. Patients must use birth&#xD;
             control during the study and for 3 months after the last dose of study drug if they&#xD;
             are sexually active.&#xD;
&#xD;
         11. Adequate organ function: Serum creatinine &lt;/=2.0 mg/dl or creatinine clearance &gt;/=60&#xD;
             mL/min, Direct bilirubin &lt;/=2.0xULN (unless considered due to leukemia involvement),&#xD;
             Alanine aminotransferase (ALT) &lt;/=2.5xULN (&lt;/=5.0xULN if considered due to leukemic&#xD;
             involvement.)&#xD;
&#xD;
         12. Adequate cardiac function: left ventricular ejection fraction (LVEF) &gt;/= 50% as&#xD;
             determined by a multigated acquisition (MUGA) scan or echocardiogram, QTc interval &lt;/=&#xD;
             480 ms;&#xD;
&#xD;
         13. Women of childbearing potential must have a pregnancy test at screening.&#xD;
&#xD;
         14. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Impaired cardiac function including any one of the following: a. Inability to monitor&#xD;
             the QT interval on ECG b. Congenital long QT syndrome or a known family history of&#xD;
             long QT syndrome. c. Clinically significant resting brachycardia (&lt;45 beats per&#xD;
             minute) d. QTc &gt; 480 msec on baseline ECG. If QTc &gt;450 msec and electrolytes are not&#xD;
             within normal ranges, electrolytes should be corrected and then the patient&#xD;
             re-screened for QTc e. Impaired cardiovascular function or clinically significant&#xD;
             cardiovascular diseases, including any of the following: History of acute coronary&#xD;
             syndromes (including myocardial infarction, unstable angina, coronary artery bypass&#xD;
             grafting, coronary angioplasty, or stenting) &lt;6 months prior to screening, Symptomatic&#xD;
             chronic heart failure, history or current evidence of clinically significant cardiac&#xD;
             arrhythmia and/or conduction abnormality &lt;6 months prior to screening except atrial&#xD;
             fibrillation and paroxysmal supraventricular tachycardia&#xD;
&#xD;
          2. History of Gilbert's syndrome.&#xD;
&#xD;
          3. Uncontrolled arterial hypertension despite medical treatment&#xD;
&#xD;
          4. Prior therapy with a MEK- inhibitor&#xD;
&#xD;
          5. History or current evidence of retinal vein occlusion (RVO) or current risk factors&#xD;
             for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity&#xD;
             or hypercoagulability syndromes)&#xD;
&#xD;
          6. History of retinal degenerative disease;&#xD;
&#xD;
          7. Patients with washout period &lt; 6 weeks from the last dose of ipilimumab or other&#xD;
             immunotherapy&#xD;
&#xD;
          8. Known positive serology for HIV, active hepatitis B, and/or active hepatitis C&#xD;
             infection&#xD;
&#xD;
          9. Patients who have neuromuscular disorders that are associated with elevated CK (e.g.,&#xD;
             inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal&#xD;
             muscular atrophy)&#xD;
&#xD;
         10. Patients who are planning on embarking on a new strenuous exercise regimen after first&#xD;
             dose of study treatment. Muscular activities, such as strenuous exercise, that can&#xD;
             result in significant increases in plasma CK levels should be avoided while on MEK162&#xD;
             treatment&#xD;
&#xD;
         11. Patients currently receiving treatment with strong CYP3A4 inhibitors who cannot&#xD;
             discontinue such treatment or be switched to a different medication prior to starting&#xD;
             study drug are excluded from study entry. Strong CYP3A4 inhibitors include the&#xD;
             following medications: itraconazole, ketoconazole, miconazole, voriconazole;&#xD;
             amprenavir, atazanavir, fosamprenavir, indinavir, nelfinavir, ritonavir;&#xD;
             ciprofloxacin, clarithromycin, diclofenac, doxycycline, enoxacin, isoniazid, ketamine,&#xD;
             nefazodone, nicardipine, propofol, quinidine, telithromycin.&#xD;
&#xD;
         12. Patients receiving treatment with any medications that have the potential to prolong&#xD;
             the QT interval who cannot discontinue such treatment or be switched to a different&#xD;
             medication prior to starting study drug are excluded from the study entry. A list of&#xD;
             anti-arrhythmic drugs and other drugs that may prolong the QT interval is added in&#xD;
             protocol section 8.5 (page 53).&#xD;
&#xD;
         13. Impaired gastrointestinal (GI) function or active GI disease that may significantly&#xD;
             alter the absorption of study drug in the opinion of the treating physician (e.g.,&#xD;
             active ulcerative diseases, uncontrolled nausea, uncontrolled vomiting, uncontrolled&#xD;
             diarrhea, active malabsorption syndrome, small bowel resection within last 1 year or&#xD;
             gastric bypass surgery within last 1 year).&#xD;
&#xD;
         14. Another active primary malignant disease, which requires systemic treatment&#xD;
             (chemotherapy or radiation)&#xD;
&#xD;
         15. History of significant congenital or acquired bleeding disorder unrelated to cancer&#xD;
&#xD;
         16. Major surgery within 4 weeks prior to Day 1 of the study or who have not recovered&#xD;
             from prior surgery.&#xD;
&#xD;
         17. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive human chorionic gonadotropin (hCG) laboratory test&#xD;
&#xD;
         18. Women of child-bearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant, unless they are using highly effective methods of contraception&#xD;
             throughout the study and for 3 months after study drug discontinuation. Highly&#xD;
             effective methods of contraception are further defined.&#xD;
&#xD;
         19. Patients who are eligible, willing and able to receive an allogeneic stem cell&#xD;
             transplant within 6 weeks are not eligible.&#xD;
&#xD;
         20. Sexually active males unless they use a condom during intercourse while taking the&#xD;
             drug and for 3 months after stopping treatment and should not father a child in this&#xD;
             period. A condom is required to be used also by vasectomized men in order to prevent&#xD;
             delivery of the drug via seminal fluid;&#xD;
&#xD;
         21. History of non-compliance to medical regimens or inability to grant consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naval Daver, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 22, 2014</study_first_submitted>
  <study_first_submitted_qc>August 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2014</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Advanced phase chronic myeloid leukemia</keyword>
  <keyword>refractory chronic phase chronic myeloid leukemia</keyword>
  <keyword>CML</keyword>
  <keyword>Accelerated phase</keyword>
  <keyword>(AP)</keyword>
  <keyword>Blast phase</keyword>
  <keyword>(BP)</keyword>
  <keyword>Philadelphia-positive acute leukemia</keyword>
  <keyword>MEK-162</keyword>
  <keyword>Nilotinib</keyword>
  <keyword>AMN107</keyword>
  <keyword>Tasigna</keyword>
  <keyword>Questionnaires</keyword>
  <keyword>Surveys</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

